La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead first-in-class inflammation/auto-immune assets, RP6503 and RP3128 in preclinical models of pulmonary fibrosis, COPD and asthma. Therapeutic potential of RP3128 in asthma will be highlighted during an oral presentation.
--- Data to be presented at European Respiratory Society (ERS) International Congress 2014, September 6-10, Munich, Germany
--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated potent anti-inflammatory and anti-fibrotic data especially in combination with Esbriet ® (pirfenidone) in preclinical models of pulmonary fibrosis
--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated significant efficacy in preclinical models relevant to COPD
--- Oral administration of RP-3128, a potent and novel CRAC channel inhibitor attenuated respiratory distress in allergen challenged guinea pig models
--- Phase 1 clinical trials (inhalation & oral route) to be initiated in 1H of 2015
Details of the poster and oral presentations:
-- Poster Title: Pre-clinical evaluation of a novel and selective PI3K delta/gamma inhibitor in pulmonary fibrosis
· Session: 160
· Presentation Date & Time: 07 September 2014; 14:45-16:45
· Session Location: Room M-1(B0)
· Poster Board Number: P1507
-- Poster Title: RP-6503, a novel and selective PI3K delta/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
· Session Information: 160
· Presentation Date & Time: 07 September 2014; 14:45-16:45
· Session Location: Room M-1(B0)
· Poster Board Number: P1504
-- Oral Presentation Title: CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs
· Session: 508
· Presentation Date & Time: 10 September 2014; 10:45-12:45
· Presentation Location: Room 14c (ICM)
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
CONTACT: Kumar V. Penmetsa, Ph.D. Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: kvp@rhizen.com
Hey, check out all the engineering jobs. Post your resume today!
